RxDoctor Payments Data

Leonard Staller

Urology · Clifton, NJNPI 1720015183

Payments from drug & device makers

$2,237in general payments, 2019–2025

Across 112 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$2K
  • Halozyme Inc$112
  • Clarus Therapeutics Inc.$69
  • 180 Medical, Inc.$59
  • Acerus Pharmaceuticals Corporation$50
  • Merck$46
  • plus $291 from 11 others

What the payments were for

  • Food & beverage$2,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,237 in reported general payments places this provider in the 50th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$38,330
Medicare patients
85
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron31$30,187
XyostedTestosterone Enanthate35$20,886
ElmironPentosan Polysulfate Sodium11$10,845
Tamsulosin Hcl499$10,807
Testosterone57$8,624
Oxybutynin Chloride ErOxybutynin Chloride98$3,613
Finasteride173$2,677
Testosterone Cypionate72$2,055
Alfuzosin Hcl ErAlfuzosin Hcl52$1,695
Dutasteride31$1,540
Solifenacin Succinate40$1,261
Doxycycline Hyclate93$1,017
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$912
Potassium Citrate ErPotassium Citrate14$869
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim53$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$14$30,18731 claims
Antares Pharma, Inc.Xyosted$1,610$20,88635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 401 urology providers in New Jersey.

Other urology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →